Literature DB >> 16845777

Human West Nile virus infection, Catalonia, Spain.

Domingo Bofill, Cristina Domingo, Neus Cardeñosa, Joan Zaragoza, Fernando de Ory, Sofia Minguell, María Paz Sánchez-Seco, Angela Domínguez, Antonio Tenorio.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16845777      PMCID: PMC3291065          DOI: 10.3201/eid1207.060164

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


× No keyword cloud information.
To the Editor: West Nile virus (WNV) is a mosquitoborne flavivirus that is widespread in Africa, the Middle East, Asia, and southern Europe, where it causes outbreaks and sporadic cases of the disease. It has become an emergent disease in North America, where it was detected for the first time in 1999 and became epidemic shortly thereafter (). Although WNV was initially considered to have a minor health effect in the Mediterranean basin, human and equine outbreaks reported in the last decade in different countries (–) have made WNV infections a public health concern. The epidemiology of WNV in Europe differs from that in America and has only been associated with nonrecurrent, sporadic outbreaks. The reasons for this difference are controversial; it may be due to environmental factors, reservoirs, or even mosquito vectors. In Spain, neither equine nor human WNV cases have been reported. However, some human serosurveys that used hemagglutination inhibition suggested that WNV or closely related flaviviruses circulated during the 1970s in the Ebro delta and areas in Spain (,). The Ebro delta, a wetland in Catalonia, in the northeast of Spain, is a stopping-off point for birds migrating between regions of Africa and Europe where different WNV vectors and reservoirs have been identified. The delta could be considered a high-risk area for WNV and other arthropodborne virus infections. To evaluate WNV seroprevalence in the human population of the Ebro delta, a survey was conducted in 2001. After obtaining informed consent, 992 serum samples were obtained from inhabitants of the area. The population studied was representative of the whole area and was stratified by sex and age. Anti-WNV immunoglobulin G (IgG) antibodies were determined by using an in-house indirect enzyme-linked immunosorbent assay (ELISA), as previously described (). Results were classified as the sample absorbance/positive control absorbance ratio. Samples showing ratio values >0.2 were tested for WNV IgG and IgM by using an indirect and a μ-chain capture ELISA, respectively (Focus Technologies, Cypress, CA, USA), and an in-house microneutralization test. For the microneutralization test, samples were tested in duplicate and assayed twice. Twofold dilutions (25 μL) of the samples (1:16–1:256 dilutions) were assayed by using 100 TCID50 (50% tissue culture infectious dose) of West Nile Eg-101 reference strain in 96-well tissue culture plates with Vero cells and after 7 days of incubation at 37°C and 5% CO2. Thirty-eight samples showed IgG ratios >0.2 by the in-house ELISA. Of these, 12 showed WNV IgG, and 1 was positive for WNV IgM and IgG, according to the Focus assays. Two samples showed positive neutralizing activity, with titers of 32 and 256. The highest titer was shown by the sample that yielded positive levels of both IgM and IgG in the ELISA, which suggests recent WNV infection. Anti-WNV IgG was more often detected in participants in the 20- to 29-year age group (odds ratio [OR] 4.23, 95% confidence interval [CI] 1.04–16.02, p = 0.03) and in persons who reported frequent mosquito bites (OR 8.62, 95% CI 0.44–169, p = 0.08). IgG-positive persons were equally divided by sex. No significant differences were found between antibody-positive or antibody-negative persons with respect to their profession, place of occupation, current residence, time in current residence, outdoor activities, use of insecticides and repellents, or symptoms related to WNV infection. No symptoms related to WNV infection were reported by the IgM/IgG-positive participant, who was 31 years of age, was born in the area, worked outdoors, and was frequently bitten by mosquitoes. He also reported travel to Cuba 1 year earlier, but he had not been vaccinated against flavivirus, and serologic test results for dengue were negative. The other IgG- and neutralizing antibody–positive participant was 45 years of age and was born and works in the area. He had never traveled abroad or been vaccinated against flavivirus. He reported a 4-day fever of unknown origin during the summer 1 or 2 years before the study. He often fishes in the areas and is frequently bitten by mosquitoes. In conclusion, the study found evidence of recent WNV infections in humans living in the Ebro delta, where previous flavivirus circulation has been suggested by Lozano and Filipe (). IgG-positive results not confirmed by neutralization could be due to cross-reactive antibodies induced by other flavivirus infections or vaccinations (,). The probable WNV infection described was asymptomatic, as occurs in ≈80% of cases. Other WNV infections in the area may have remained undetected, including neuroinvasive cases. Intensified research and surveillance in this area will help determine and refine thresholds for public health interventions.
  9 in total

1.  Identification of a Kunjin/West Nile-like flavivirus in brains of patients with New York encephalitis.

Authors:  T Briese; X Y Jia; C Huang; L J Grady; W I Lipkin
Journal:  Lancet       Date:  1999-10-09       Impact factor: 79.321

Review 2.  Serodiagnosis of flaviviral infections and vaccinations in humans.

Authors:  Goro Kuno
Journal:  Adv Virus Res       Date:  2003       Impact factor: 9.937

3.  Antibodies to arboviruses in northwestern Spain.

Authors:  M T González; A R Filipe
Journal:  Am J Trop Med Hyg       Date:  1977-07       Impact factor: 2.345

Review 4.  West Nile in the Mediterranean basin: 1950-2000.

Authors:  B Murgue; S Murri; H Triki; V Deubel; H G Zeller
Journal:  Ann N Y Acad Sci       Date:  2001-12       Impact factor: 5.691

5.  West Nile outbreak in horses in southern France, 2000: the return after 35 years.

Authors:  B Murgue; S Murri; S Zientara; B Durand; J P Durand; H Zeller
Journal:  Emerg Infect Dis       Date:  2001 Jul-Aug       Impact factor: 6.883

6.  Performance of immunoglobulin G (IgG) and IgM enzyme-linked immunosorbent assays using a West Nile virus recombinant antigen (preM/E) for detection of West Nile virus- and other flavivirus-specific antibodies.

Authors:  Wayne R Hogrefe; Ronald Moore; Mary Lape-Nixon; Michael Wagner; Harry E Prince
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

7.  [Antibodies against the West Nile virus and other arthropod-transmitted viruses in the Ebro Delta region].

Authors:  A Lozano; A R Filipe
Journal:  Rev Esp Salud Publica       Date:  1998 May-Jun

8.  Human West Nile virus, France.

Authors:  Pascal Del Giudice; Isabel Schuffenecker; Fréderic Vandenbos; Evelyne Counillon; Hervé Zellet
Journal:  Emerg Infect Dis       Date:  2004-10       Impact factor: 6.883

9.  West Nile virus in Morocco, 2003.

Authors:  Isabelle Schuffenecker; Christophe N Peyrefitte; Mohammed el Harrak; Séverine Murri; Agnès Leblond; Hervé G Zeller
Journal:  Emerg Infect Dis       Date:  2005-02       Impact factor: 6.883

  9 in total
  9 in total

Review 1.  Impact of climate change and other factors on emerging arbovirus diseases.

Authors:  E A Gould; S Higgs
Journal:  Trans R Soc Trop Med Hyg       Date:  2008-09-16       Impact factor: 2.184

2.  West Nile fever outbreak in horses and humans, Spain, 2010.

Authors:  Ignacio García-Bocanegra; Juan A Jaén-Téllez; Sebastián Napp; Antonio Arenas-Montes; Manuel Fernández-Morente; Vicente Fernández-Molera; Antonio Arenas
Journal:  Emerg Infect Dis       Date:  2011-12       Impact factor: 6.883

3.  Phenotypic insecticide resistance in arbovirus mosquito vectors in Catalonia and its capital Barcelona (Spain).

Authors:  Krijn Paaijmans; Marco Brustollin; Carles Aranda; Roger Eritja; Sandra Talavera; Nonito Pagès; Silvie Huijben
Journal:  PLoS One       Date:  2019-07-05       Impact factor: 3.240

4.  Seroconversion in wild birds and local circulation of West Nile virus, Spain.

Authors:  Jordi Figuerola; Ramon Soriguer; Gema Rojo; Concepción Gómez Tejedor; Miguel Angel Jimenez-Clavero
Journal:  Emerg Infect Dis       Date:  2007-12       Impact factor: 6.883

5.  West Nile virus in golden eagles, Spain, 2007.

Authors:  Miguel Angel Jiménez-Clavero; Elena Sotelo; Jovita Fernandez-Pinero; Francisco Llorente; Juan Manuel Blanco; Julia Rodriguez-Ramos; Elisa Perez-Ramirez; Ursula Höfle
Journal:  Emerg Infect Dis       Date:  2008-09       Impact factor: 6.883

6.  Experimental studies on comparison of the vector competence of four Italian Culex pipiens populations for West Nile virus.

Authors:  Claudia Fortuna; Maria Elena Remoli; Marco Di Luca; Francesco Severini; Luciano Toma; Eleonora Benedetti; Paola Bucci; Fabrizio Montarsi; Giada Minelli; Daniela Boccolini; Roberto Romi; Maria Grazia Ciufolini
Journal:  Parasit Vectors       Date:  2015-09-17       Impact factor: 3.876

7.  Circulation of a Meaban-like virus in yellow-legged gulls and seabird ticks in the western Mediterranean basin.

Authors:  Audrey Arnal; Elena Gómez-Díaz; Marta Cerdà-Cuéllar; Sylvie Lecollinet; Jessica Pearce-Duvet; Núria Busquets; Ignacio García-Bocanegra; Nonito Pagès; Marion Vittecoq; Abdessalem Hammouda; Boudjéma Samraoui; Romain Garnier; Raül Ramos; Slaheddine Selmi; Jacob González-Solís; Elsa Jourdain; Thierry Boulinier
Journal:  PLoS One       Date:  2014-03-13       Impact factor: 3.240

Review 8.  A review of the vector management methods to prevent and control outbreaks of West Nile virus infection and the challenge for Europe.

Authors:  Romeo Bellini; Herve Zeller; Wim Van Bortel
Journal:  Parasit Vectors       Date:  2014-07-11       Impact factor: 3.876

Review 9.  [Imported infectious diseases in Spain].

Authors:  Gerardo Rojo Marcos; Juan Cuadros González; Alberto Arranz Caso
Journal:  Med Clin (Barc)       Date:  2008-10-25       Impact factor: 1.725

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.